In particular, IgD+ CD38dim %B cell on 1-oleoyl-GPC (18:1) levels, memory B cell %lymphocyte on AMP levels, CD39+ resting Treg AC on DMTPA levels, CD45RA+ CD8br AC on DMTPA levels, CD45RA+ CD8br AC on X-12680 levels, DN (CD4−CD8−) AC on 3-hydroxyoctanoylcarnitine (2) levels, CD3 on Naive CD4+ on 1-oleoyl-GPC (18,1) levels, and FSC-A on myeloid DC on X-12544 levels were associated with reduced epilepsy risk. The gene discussed is ENTPD1; the disease is epilepsy.